Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
286.98
-6.47 (-2.20%)
At close: May 15, 2026, 4:00 PM EDT
293.80
+6.82 (2.38%)
After-hours: May 15, 2026, 7:34 PM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,500 employees as of December 31, 2025. The number of employees increased by 270 or 12.11% compared to the previous year.
Employees
2,500
Change (1Y)
270
Growth (1Y)
12.11%
Revenue / Employee
$1,714,769
Profits / Employee
$215,196
Market Cap
38.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,500 | 270 | 12.11% |
| Dec 31, 2024 | 2,230 | 130 | 6.19% |
| Dec 31, 2023 | 2,100 | 98 | 4.90% |
| Dec 31, 2022 | 2,002 | 337 | 20.24% |
| Dec 31, 2021 | 1,665 | 212 | 14.59% |
| Dec 31, 2020 | 1,453 | 130 | 9.83% |
| Dec 31, 2019 | 1,323 | 258 | 24.23% |
| Dec 31, 2018 | 1,065 | 316 | 42.19% |
| Dec 31, 2017 | 749 | 235 | 45.72% |
| Dec 31, 2016 | 514 | 145 | 39.30% |
| Dec 31, 2015 | 369 | 113 | 44.14% |
| Dec 31, 2014 | 256 | 91 | 55.15% |
| Dec 31, 2013 | 165 | 36 | 27.91% |
| Dec 31, 2012 | 129 | 13 | 11.21% |
| Dec 31, 2011 | 116 | -56 | -32.56% |
| Dec 31, 2010 | 172 | -6 | -3.37% |
| Dec 31, 2009 | 178 | 8 | 4.71% |
| Dec 31, 2008 | 170 | 41 | 31.78% |
| Dec 31, 2007 | 129 | 7 | 5.74% |
| Dec 31, 2006 | 122 | 28 | 29.79% |
| Dec 31, 2005 | 94 | 23 | 32.39% |
| Dec 31, 2004 | 71 | 11 | 18.33% |
| Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Incyte | 2,844 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
ALNY News
- 4 days ago - Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Alnylam announces new analyses from HELIOS-B study of vutrisiran - TheFly
- 5 days ago - New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden - Business Wire
- 10 days ago - MBX Biosciences appoints Mark Soued as chief commercial officer. - TheFly
- 10 days ago - Alnylam to Webcast Presentations at Upcoming Investor Conferences - Business Wire
- 13 days ago - Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM - Business Wire
- 16 days ago - Alnylam price target raised to $370 from $360 at Morgan Stanley - TheFly
- 16 days ago - Alnylam price target lowered to $447 from $448 at Bernstein - TheFly